Predicting response to immunotherapy in metastatic melanoma by a personalized mathematical model
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Stuttgart, Universität Stuttgart, Dissertation, 2020
- Schlagwort
-
Melanoma
Immunotherapy
- Ereignis
-
Veröffentlichung
- (wo)
-
Stuttgart
- (wer)
-
Universitätsbibliothek der Universität Stuttgart
- (wann)
-
2020
- Urheber
- Beteiligte Personen und Organisationen
-
Morrison, Markus
- DOI
-
10.18419/opus-10952
- URN
-
urn:nbn:de:bsz:93-opus-ds-109699
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tsur, Neta
- Morrison, Markus
- Universitätsbibliothek der Universität Stuttgart
Entstanden
- 2020
Ähnliche Objekte (12)
Mixed Response to Immunotherapy in Patients with Metastatic Melanoma
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment
Antigen-specific TIL therapy for melanoma: a flexible platform for personalized cancer immunotherapy
Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma
Immunotherapy of malignant melanoma
Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial
Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma
The role of biomarkers in personalized immunotherapy
METASTATIC MALIGNANT MELANOMA OF SKIN
Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy
Metastatic melanoma to small bowel: metastasectomy is supported in the era of immunotherapy and checkpoint inhibitors
Mixed Response to Immunotherapy in Patients with Metastatic Melanoma
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment
Antigen-specific TIL therapy for melanoma: a flexible platform for personalized cancer immunotherapy
Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma
Immunotherapy of malignant melanoma
Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial
Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma
The role of biomarkers in personalized immunotherapy
METASTATIC MALIGNANT MELANOMA OF SKIN
Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy
Metastatic melanoma to small bowel: metastasectomy is supported in the era of immunotherapy and checkpoint inhibitors
Mixed Response to Immunotherapy in Patients with Metastatic Melanoma
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment
Antigen-specific TIL therapy for melanoma: a flexible platform for personalized cancer immunotherapy
Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma
Immunotherapy of malignant melanoma
Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial
Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma
The role of biomarkers in personalized immunotherapy
METASTATIC MALIGNANT MELANOMA OF SKIN
Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy